Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Week in Review: TAVR vs. SAVR | FDA clears AI tech | Payment model confusion | Private equity & cardiology | Injuries after PCI
Saturday, June 27, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

This Week’s News

Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis

TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.

READ MORE >
heart doctor cardiologist
Share on Twitter Share on Facebook Share on Linkedin

Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis

Share on Twitter Share on Facebook Share on Linkedin
heart doctor cardiologist
TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.
READ MORE >

AI company founded by cardiologist gains FDA clearance, raises $8.5M

“We have colonoscopies, we have mammograms, but we have not had equivalents for most forms of heart disease,”  Pierre Elias, MD, Pathway Labs founder and CEO, explained.

READ MORE >
robot reviewing heart data
Share on Twitter Share on Facebook Share on Linkedin

AI company founded by cardiologist gains FDA clearance, raises $8.5M

Share on Twitter Share on Facebook Share on Linkedin
robot reviewing heart data
“We have colonoscopies, we have mammograms, but we have not had equivalents for most forms of heart disease,”  Pierre Elias, MD, Pathway Labs founder and CEO, explained.
READ MORE >

Hundreds of cardiologists incorrectly added to new mandatory payment model

When CMS shared a list of cardiologists being targeted with a brand new payment model, the American College of Cardiology identified a long list of apparent mistakes.

READ MORE >
doctor_patients.jpg
Share on Twitter Share on Facebook Share on Linkedin

Hundreds of cardiologists incorrectly added to new mandatory payment model

Share on Twitter Share on Facebook Share on Linkedin
doctor_patients.jpg
When CMS shared a list of cardiologists being targeted with a brand new payment model, the American College of Cardiology identified a long list of apparent mistakes.
READ MORE >

FDA clears AI software for flagging signs of vascular disease

The newly cleared software alerts clinicians when it detects a suspected vascular occlusion.

READ MORE >
artificial intelligence AI explainable ethical responsible
Share on Twitter Share on Facebook Share on Linkedin

FDA clears AI software for flagging signs of vascular disease

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence AI explainable ethical responsible
The newly cleared software alerts clinicians when it detects a suspected vascular occlusion.
READ MORE >

Private equity unlikely to dominate cardiology despite hype

Medaxiom CEO Jerry Blackwell, MD, MBA, FACC, discusses investor's interest in buying cardiology practices, noting that PE ownership remains relatively low.

READ MORE >
Medaxiom CEO Jerry Blackwell, MD, explains the role of private equity in cardiology and that it is a small player in cardiology practice ownership.
Share on Twitter Share on Facebook Share on Linkedin

Private equity unlikely to dominate cardiology despite hype

Share on Twitter Share on Facebook Share on Linkedin
Medaxiom CEO Jerry Blackwell, MD, explains the role of private equity in cardiology and that it is a small player in cardiology practice ownership.
Medaxiom CEO Jerry Blackwell, MD, MBA, FACC, discusses investor's interest in buying cardiology practices, noting that PE ownership remains relatively low.
READ MORE >

New digital platform gets clinicians on the same page when treating heart attacks

One of the platform's biggest benefits is the rich clinical information it provides to all members of the care team.

READ MORE >
 Derek Pineda, FNP, CCRN, RCIS, FACC, with Mount Sinai Fuster Heart Hospital, explains the use of a digital app platform for STEMI team coordination that helped his health system improve STEMI outcomes.
Share on Twitter Share on Facebook Share on Linkedin

New digital platform gets clinicians on the same page when treating heart attacks

Share on Twitter Share on Facebook Share on Linkedin
 Derek Pineda, FNP, CCRN, RCIS, FACC, with Mount Sinai Fuster Heart Hospital, explains the use of a digital app platform for STEMI team coordination that helped his health system improve STEMI outcomes.
One of the platform's biggest benefits is the rich clinical information it provides to all members of the care team.
READ MORE >

Thousands of heart surgery kits recalled due to FDA quality concerns

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

READ MORE >
FDA recall medical device recall product recall
Share on Twitter Share on Facebook Share on Linkedin

Thousands of heart surgery kits recalled due to FDA quality concerns

Share on Twitter Share on Facebook Share on Linkedin
FDA recall medical device recall product recall
Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.
READ MORE >

First US patient enrolled in device study to reduce coronary microvascular dysfunction

The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.

READ MORE >
The A-FLUX Reducer System from VahatiCor is designed to treat coronary microvascular dysfunction.
Share on Twitter Share on Facebook Share on Linkedin

First US patient enrolled in device study to reduce coronary microvascular dysfunction

Share on Twitter Share on Facebook Share on Linkedin
The A-FLUX Reducer System from VahatiCor is designed to treat coronary microvascular dysfunction.
The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.
READ MORE >

Blood may leak out of Impella introducers due to manufacturing defect

Eight reports of major bleeding have been reported from Impella introducers, prompting the FDA early alert this week. 

READ MORE >
Impella users need to monitor for blood leaks at the sidearm and hub of the introducer sheath shown below here introducers.
Share on Twitter Share on Facebook Share on Linkedin

Blood may leak out of Impella introducers due to manufacturing defect

Share on Twitter Share on Facebook Share on Linkedin
Impella users need to monitor for blood leaks at the sidearm and hub of the introducer sheath shown below here introducers.
Eight reports of major bleeding have been reported from Impella introducers, prompting the FDA early alert this week. 
READ MORE >

Chest pain drug lowers risk of kidney injury after PCI

Treating certain high-risk PCI patients with nicorandil before and after treatment can significantly reduce their risk of contrast-related injuries.

READ MORE >
pills-384846_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

Chest pain drug lowers risk of kidney injury after PCI

Share on Twitter Share on Facebook Share on Linkedin
pills-384846_960_720.jpg
Treating certain high-risk PCI patients with nicorandil before and after treatment can significantly reduce their risk of contrast-related injuries.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup